The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung, colon and ovarian cancers.

Fatty liver disease, now called MASLD, is increasingly linked to liver cancer due to long-term inflammation and liver cell ...

Researchers added paricalcitol to chemotherapy and assessed outcomes in metastatic pancreatic cancer. The treatment remodeled ...

Preclinical studies at the Salk Institute laid the foundation for a question now being tested in patients: Can a vitamin ...

A small clinical trial led by Dana-Farber Cancer Institute researchers put a Salk Institute idea to the test in patients: that ...

A small clinical trial led by Dana-Farber Cancer Institute researchers put a Salk Institute idea to the test in patients: ...

Indore (Madhya Pradesh): Rapid advancements in medical technology are transforming complex liver and pancreas surgeries, making them safer, more precise, and less risky for patients. Experts from ...

A small clinical trial led by Dana-Farber Cancer Institute researchers has put a Salk Institute idea to the test in patients: ...

Pemvidutide improves fibrosis markers, liver fat, lipids, weight, and blood pressure in patients with MASH at 1 year, phase 2b data show.

The new strategy also holds promise for lung and colon tumors. Here’s how scientists discovered it. The new strategy also holds promise for lung and colon tumors. Here’s how scientists discovered it.

An experimental pancreatic cancer drug that’s been shown to double survival in patients with advanced stages of the disease is poised to revolutionize the way the cancer is treated, oncologists say.